# Biolex Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biolex-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.biolex.com
- Total disclosed funding: $133M
- Latest round: Series D (Oct 6, 2008)
- Investors on record: 18

## About

Biolex Therapeutics, Inc. is a biopharmaceutical company based in North Carolina, US. It offers Locteron, a controlled-release interferon alfa for the treatment of hepatitis C; BLX-155, a thrombolytic or clot buster to dissolve blood clots; and BLX-301, an antibody for the treatment of B-cell lymphoma.

## Funding rounds

- Series D, Oct 6, 2008, $60M — Intersouth Partners, OrbiMed Advisors, Pitango, Quaker Partners Management, Mitsui Global Investment, Johnson & Johnson Innovation, Clarus Ventures, Patricia Industries, JP Morgan Asset Management, The Dow Chemical Company
- Series C, May 24, 2007, $30M — Intersouth Partners, Quaker Partners Management, Polaris Partners, Easton Capital Investment Group, Mitsui Global Investment, Johnson & Johnson Innovation, Patricia Industries, Dow Venture Capital, JP Morgan Asset Management
- Series B, Sep 1, 2005, $36M — Intersouth Partners, Quaker Partners Management, Dogwood Equity, Polaris Partners, Kitty Hawk Capital, Mitsui Global Investment, Johnson & Johnson Innovation
- Series C, Dec 5, 2000, $6.5M — Intersouth Partners, Kitty Hawk Capital, Wakefield Group, Tall Oaks Capital, Franklin Street Capital

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series C, Series B, Series D
- Kitty Hawk Capital (https://capitalatlas.ai/funds/kitty-hawk-capital) — Series C, Series B
- Wakefield Group (https://capitalatlas.ai/funds/wakefield-group) — Series C
- Tall Oaks Capital (https://capitalatlas.ai/funds/tall-oaks-capital) — Series C
- Franklin Street Capital — Series C
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series B, Series C, Series D
- Dogwood Equity (https://capitalatlas.ai/funds/dogwood-equity) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series C
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series B, Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C, Series D
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series C
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series C, Series D
- Dow Venture Capital (https://capitalatlas.ai/funds/dow-venture-capital) — Series C
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- Pitango (https://capitalatlas.ai/funds/pitango) — Series D
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series D
- The Dow Chemical Company — Series D